COVID-19 Diagnostic Strategies. Part I: Nucleic Acid-Based Technologies
The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused respiratory infection, resulting in more than two million deaths globally and hospitalizing thousands of people by March 2021. A considerable percentage of the SARS-CoV-2 positive patients are asymptomatic or pre-sympt...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Bioengineering |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-5354/8/4/49 |
| _version_ | 1797537315277504512 |
|---|---|
| author | Tina Shaffaf Ebrahim Ghafar-Zadeh |
| author_facet | Tina Shaffaf Ebrahim Ghafar-Zadeh |
| author_sort | Tina Shaffaf |
| collection | DOAJ |
| description | The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused respiratory infection, resulting in more than two million deaths globally and hospitalizing thousands of people by March 2021. A considerable percentage of the SARS-CoV-2 positive patients are asymptomatic or pre-symptomatic carriers, facilitating the viral spread in the community by their social activities. Hence, it is critical to have access to commercialized diagnostic tests to detect the infection in the earliest stages, monitor the disease, and follow up the patients. Various technologies have been proposed to develop more promising assays and move toward the mass production of fast, reliable, cost-effective, and portable PoC diagnostic tests for COVID-19 detection. Not only COVID-19 but also many other pathogens will be able to spread and attach to human bodies in the future. These technologies enable the fast identification of high-risk individuals during future hazards to support the public in such outbreaks. This paper provides a comprehensive review of current technologies, the progress in the development of molecular diagnostic tests, and the potential strategies to facilitate innovative developments in unprecedented pandemics. |
| first_indexed | 2024-03-10T12:14:20Z |
| format | Article |
| id | doaj.art-534309dd77364d75bce1e4e65ec10b12 |
| institution | Directory Open Access Journal |
| issn | 2306-5354 |
| language | English |
| last_indexed | 2024-03-10T12:14:20Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Bioengineering |
| spelling | doaj.art-534309dd77364d75bce1e4e65ec10b122023-11-21T15:58:17ZengMDPI AGBioengineering2306-53542021-04-01844910.3390/bioengineering8040049COVID-19 Diagnostic Strategies. Part I: Nucleic Acid-Based TechnologiesTina Shaffaf0Ebrahim Ghafar-Zadeh1Biologically Inspired Sensors and Actuators Laboratory (BioSA), York University, Toronto, ON M3J1P3, CanadaBiologically Inspired Sensors and Actuators Laboratory (BioSA), York University, Toronto, ON M3J1P3, CanadaThe novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused respiratory infection, resulting in more than two million deaths globally and hospitalizing thousands of people by March 2021. A considerable percentage of the SARS-CoV-2 positive patients are asymptomatic or pre-symptomatic carriers, facilitating the viral spread in the community by their social activities. Hence, it is critical to have access to commercialized diagnostic tests to detect the infection in the earliest stages, monitor the disease, and follow up the patients. Various technologies have been proposed to develop more promising assays and move toward the mass production of fast, reliable, cost-effective, and portable PoC diagnostic tests for COVID-19 detection. Not only COVID-19 but also many other pathogens will be able to spread and attach to human bodies in the future. These technologies enable the fast identification of high-risk individuals during future hazards to support the public in such outbreaks. This paper provides a comprehensive review of current technologies, the progress in the development of molecular diagnostic tests, and the potential strategies to facilitate innovative developments in unprecedented pandemics.https://www.mdpi.com/2306-5354/8/4/49COVID-19 diagnosticsNA-based testsSARS-CoV-2point-of-care (PoC) detectionpolymerase chain reaction (PCR), sequencingmicroarray |
| spellingShingle | Tina Shaffaf Ebrahim Ghafar-Zadeh COVID-19 Diagnostic Strategies. Part I: Nucleic Acid-Based Technologies Bioengineering COVID-19 diagnostics NA-based tests SARS-CoV-2 point-of-care (PoC) detection polymerase chain reaction (PCR), sequencing microarray |
| title | COVID-19 Diagnostic Strategies. Part I: Nucleic Acid-Based Technologies |
| title_full | COVID-19 Diagnostic Strategies. Part I: Nucleic Acid-Based Technologies |
| title_fullStr | COVID-19 Diagnostic Strategies. Part I: Nucleic Acid-Based Technologies |
| title_full_unstemmed | COVID-19 Diagnostic Strategies. Part I: Nucleic Acid-Based Technologies |
| title_short | COVID-19 Diagnostic Strategies. Part I: Nucleic Acid-Based Technologies |
| title_sort | covid 19 diagnostic strategies part i nucleic acid based technologies |
| topic | COVID-19 diagnostics NA-based tests SARS-CoV-2 point-of-care (PoC) detection polymerase chain reaction (PCR), sequencing microarray |
| url | https://www.mdpi.com/2306-5354/8/4/49 |
| work_keys_str_mv | AT tinashaffaf covid19diagnosticstrategiespartinucleicacidbasedtechnologies AT ebrahimghafarzadeh covid19diagnosticstrategiespartinucleicacidbasedtechnologies |